Journal of Medicinal Chemistry · 2023 · 20 citations · 22 references
Life SciencesMolecular BiologyOncologyDrug DiscoveryMolecular OncologySignal TransductionAutophagy In CancerPhosphoinositide SignalingProstate CancerProtein DegradationProtein Kinase CascadesProteolytic EnzymesCellular VacuolizationCytoplasmic VacuolizationInhibitor SelectivityIntraperitoneal AdministrationPhosphoinositide KinasesTargeted Protein DegradationTherapeutic Target IdentificationTumor Cell Proliferation
High Resolution Image Download MS PowerPoint Slide The phosphoinositide kinase PIKfyve has emerged as a new potential therapeutic target in various cancers. However, limited clinical progress has been achieved with PIKfyve inhibitors. Here, we report the discovery of a first-in-class PIKfyve degrader 12d (PIK5-12d) by employing the proteolysis-targeting chimera approach. PIK5-12d potently degraded PIKfyve protein with a DC 50 value of 1.48 nM and a D max value of 97.7% in prostate cancer VCaP cells. Mechanistic studies revealed that it selectively induced PIKfyve degradation in a VHL- and proteasome-dependent manner. PIKfyve degradation by PIK5-12d caused massive cytoplasmic vacuolization and blocked autophagic flux in multiple prostate cancer cell lines. Importantly, PIK5-12d was more effective in suppressing the growth of prostate cancer cells than the parent inhibitor and exerted prolonged inhibition of downstream signaling. Further, intraperitoneal administration of PIK5-12d exhibited potent PIKfyve degradation and suppressed tumor proliferation in vivo. Overall, PIK5-12d is a valuable chemical tool for exploring PIKfyve-based targeted therapy.
22
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Lanbo Xiao, Abhijit Parolia, Yuanyuan Qiao et al. · Nature · 2021 · 317 citations · Full text
PIKfyve Regulation of Endosome‐Linked Pathways
Jane De Lartigue, Hannah E.J. Polson, Morri E. Feldman et al. · Traffic · 2009 · 240 citations · Full text